SLC5A2 and type 2 diabetes mellitus: Inhibitors of sodium-glucose cotransporter 2 (SGLT2) constitute another class of drugs used to treat T2D, which apart from reducing blood glucose levels and body mass, enhance autophagy and lysosomal degradation [95].